secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTENSITY THERAPEUTICS, INC. (INTS)
CIK:        0001567264
Form:       8-K
Filed at:   2023-12-12T23:59:59+00:00
Accession:  0001213900-23-094884
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intensity Therapeutics appoints Joseph Talamo as CFO; John Wesolowski returns to Controller role
--------------------------------------------------------------------------------

- Joseph Talamo appointed CFO effective Dec 11, 2023; replaces interim CFO John Wesolowski.
- Talamo brings 25+ years biopharma experience; previously CFO of HiberCell and Caladrius Biosciences.
- Compensation: $370k base salary, 35% target bonus, 80,000 options at $6.88 exercise price (4-year vest).
- Wesolowski remains as Principal Accounting Officer and Controller.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567264/000121390023094884/0001213900-23-094884-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567264/000121390023094884/ea189864-8k_intensity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-094884

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer